280 related articles for article (PubMed ID: 12063863)
21. Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy.
Tajima T; Tsubaki J; Ishizu K; Jo W; Ishi N; Fujieda K
Endocr J; 2008 Jul; 55(3):595-9. PubMed ID: 18445999
[TBL] [Abstract][Full Text] [Related]
22. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.
Schoof E; Dörr HG; Kiess W; Lüdecke DK; Freitag E; Zindel V; Rascher W; Dötsch J
Horm Res; 2004; 61(4):184-9. PubMed ID: 14739526
[TBL] [Abstract][Full Text] [Related]
23. Acromegaly and its treatment in the McCune-Albright syndrome.
Premawardhana LD; Vora JP; Mills R; Scanlon MF
Clin Endocrinol (Oxf); 1992 Jun; 36(6):605-8. PubMed ID: 1424186
[TBL] [Abstract][Full Text] [Related]
24. Acromegaly, multinodular goiter and silent polyostotic fibrous dysplasia. A variant of the McCune-Albright syndrome.
Abs R; Beckers A; Van de Vyver FL; De Schepper A; Stevenaert A; Hennen G
J Endocrinol Invest; 1990 Sep; 13(8):671-5. PubMed ID: 2273209
[TBL] [Abstract][Full Text] [Related]
25. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
Turner HE; Thornton-Jones VA; Wass JA
Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
[TBL] [Abstract][Full Text] [Related]
26. Transsphenoidal surgery in a patient with acromegaly and McCune-Albright syndrome: application of neuronavigation.
Dou W; Lin N; Ma W; Yang Y; Zhu H; Sun J; Lian W; Yang Z; Li W; Wang R
J Neurosurg; 2008 Jan; 108(1):164-9. PubMed ID: 18173327
[TBL] [Abstract][Full Text] [Related]
27. Osteosarcoma in a pregnant patient with McCune-Albright syndrome.
Kanazawa I; Yamauchi M; Yano S; Imanishi Y; Kitazawa R; Nariai Y; Araki A; Kobayashi K; Inaba M; Maruyama R; Yamaguchi T; Sugimoto T
Bone; 2009 Sep; 45(3):603-8. PubMed ID: 19481621
[TBL] [Abstract][Full Text] [Related]
28. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
Biermasz NR; Pereira AM; Smit JW; Romijn JA; Roelfsema F
Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
[TBL] [Abstract][Full Text] [Related]
29. Paediatric management of endocrine complications in McCune-Albright syndrome.
Zacharin M
J Pediatr Endocrinol Metab; 2005 Jan; 18(1):33-41. PubMed ID: 15679067
[TBL] [Abstract][Full Text] [Related]
30. McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases.
Chanson P; Dib A; Visot A; Derome PJ
Eur J Endocrinol; 1994 Sep; 131(3):229-34. PubMed ID: 7921205
[TBL] [Abstract][Full Text] [Related]
31. Clinical, endocrinological and radiography features in a child with McCune-Albright syndrome and pituitary adenoma.
Zumkeller W; Jassoy A; Lebek S; Nagel M
J Pediatr Endocrinol Metab; 2001 May; 14(5):553-9. PubMed ID: 11393578
[TBL] [Abstract][Full Text] [Related]
32. A follow-up of 130 patients with acromegaly in a single centre.
Bolanowski M; Zatonska K; Kaluzny M; Zielinski G; Bednarek-Tupikowska G; Bohdanowicz-Pawlak A; Daroszewski J; Szymczak J; Podgorski JK
Neuro Endocrinol Lett; 2006 Dec; 27(6):828-32. PubMed ID: 17187024
[TBL] [Abstract][Full Text] [Related]
33. Gigantism treated by pure endoscopic endonasal approach in a case of McCune-Albright syndrome with sphenoid fibrous dysplasia: a case report.
Sharifi G; Jalessi M; Sarvghadi F; Farhadi M
J Neurol Surg A Cent Eur Neurosurg; 2013 Dec; 74 Suppl 1():e140-4. PubMed ID: 23307306
[TBL] [Abstract][Full Text] [Related]
34. Difficulties in diagnosis and treatment of acromegaly in a patient with a McCune-Albright syndrome. A case report and a review of literature.
Baszko-Błaszyk D; Slynko J; Liebert W; Sosnowski P; Sowiński J; Waśko R
Neuro Endocrinol Lett; 2010; 31(5):594-6. PubMed ID: 21173751
[TBL] [Abstract][Full Text] [Related]
35. Clinical Characteristics and Management of Patients With McCune-Albright Syndrome With GH Excess and Precocious Puberty: A Case Series and Literature Review.
Zhai X; Duan L; Yao Y; Xing B; Deng K; Wang L; Feng F; Liang Z; You H; Yang H; Lu L; Chen S; Wang R; Pan H; Zhu H
Front Endocrinol (Lausanne); 2021; 12():672394. PubMed ID: 34777239
[TBL] [Abstract][Full Text] [Related]
36. Autonomous growth hormone secretion due to McCune Albright syndrome in paediatric age group: an ominous triad.
Jayant SS; Walia R; Gupta R; Pal R; Chaudhary S; Agrawal K; Rastogi A; Bhattacharya A; Dutta P; Bhadada SK; Bhansali A
Endocrine; 2023 Jul; 81(1):149-159. PubMed ID: 36877453
[TBL] [Abstract][Full Text] [Related]
37. McCune Albright Syndrome (MCAS): a case series.
Rao S; Colaco MP; Desai MP
Indian Pediatr; 2003 Jan; 40(1):29-35. PubMed ID: 12554915
[TBL] [Abstract][Full Text] [Related]
38. Octreotide therapy of growth hormone excess in the McCune-Albright syndrome.
Sherman SI; Ladenson PW
J Endocrinol Invest; 1992 Mar; 15(3):185-90. PubMed ID: 1624678
[TBL] [Abstract][Full Text] [Related]
39. Acromegaly caused by a growth hormone-releasing hormone secreting carcinoid tumour of the lung: the effect of octreotide treatment.
de Jager CM; de Heide LJ; van den Berg G; Wolthuis A; van Schelven WD
Neth J Med; 2007; 65(7):263-6. PubMed ID: 17656813
[TBL] [Abstract][Full Text] [Related]
40. Octreotide treatment of acromegaly during pregnancy.
Mikhail N
Mayo Clin Proc; 2002 Mar; 77(3):297-8. PubMed ID: 11888040
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
